Undisclosed Program 2

About Transneural Therapeutics

Transneural Therapeutics is a private, pre-clinical stage biotech developing a pipeline of novel, rapid-acting neuroplastogens for neuropsychiatric disorders. The company leverages a seasoned leadership team with extensive CNS drug development and commercialization experience, and integrates artificial intelligence with traditional drug discovery to identify and synthesize new compounds. Its initial focus is on lead asset TN-001 and two other programs targeting major depressive disorder (MDD), PTSD, and other conditions with high unmet need.

About Senex Biotechnology

Senex Biotechnology, founded in 2005, is a private, preclinical-stage biotech company targeting cancer drug resistance and metastasis through a novel biological pathway associated with cellular senescence. Its core platform, born from founder Igor Roninson's academic research, identifies unique drug targets required by tumor cells but not normal tissues. The lead program, a highly selective small-molecule inhibitor, is anticipated to enter clinical trials within a year for difficult-to-treat cancers. The company has a strong grant-funded foundation, with 16 awards from entities like the NIH and DoD, and is led by a seasoned team with deep expertise in oncology drug development.

About FIMECS

Japanese biotech developing targeted protein degradation drugs for undruggable oncology targets using its proprietary RaPPIDS™ platform.

Therapeutic Areas

Other Neuropsychiatric Disorders Drugs